Stock MIST MILESTONE PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-21 EDT 		5-day change 1st Jan Change
1.38 USD -0.72% Intraday chart for Milestone Pharmaceuticals Inc. -2.13% -17.37%
06-20 Transcript : Milestone Pharmaceuticals Inc. - Special Call
05-29 Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Milestone Pharmaceuticals Inc. - Special Call
Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024
AQ
Milestone Pharmaceuticals : Corporate Presentation
PU
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
AQ
Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia
MT
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
AQ
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST?
CI
Certain Pre-Funded Warrants of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
CI
Certain Options of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
CI
Certain Common Shares of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
CI
Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness
AQ
Milestone Pharmaceuticals: Q1 Earnings Snapshot
AQ
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
AQ
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Milestone Pharmaceuticals : Corporate Presentation
PU
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
AQ
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
AQ
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
AQ
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
CI
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIST Stock
  4. News Milestone Pharmaceuticals Inc.